Kevin J. Hodgetts – författare

Provides insights into the drug discovery innovations that are shaping future CNS therapies In the vast field of neuroscience, drug discovery targeting the central nervous system (CNS) presents both extraordinary opportunities and complex challenges. Disorders such as Alzheimer’s disease, schizophrenia, and epilepsy affect millions worldwide, demanding innovative therapeutic strategies. Yet understanding brain processes and overcoming the blood-brain barrier continue to pose significant hurdles for researchers and developers alike. Trends in CNS Drug Discovery offers a comprehensive overview of the methodologies, successes, and challenges shaping this critical area of pharmaceutical research. Covering a wide range of key areas, from current therapeutic paradigms to emerging technologies, this state-of-the-art volume brings together expertise from leading scientists and drug developers who address the role of cannabinoids and psychedelics in advancing CNS therapeutics, discuss emerging modalities such as protein degraders and allosteric modulators, examine funding strategies and academic-industrial collaborations, highlight advancements in brain-penetrating cancer treatments and other high-impact areas, and more. Explores cutting-edge methodologies, including biomarkers, animal models, and brain imaging for CNS drug discoveryReviews innovative therapies such as combination drugs and prodrugs for improved treatment outcomesAnalyzes challenges in targeting diseases including Alzheimer’s and schizophrenia with novel therapeutic strategiesIncludes real-world case studies demonstrating achievements and lessons in CNS drug developmentA critical reference for academic researchers and industry professionals in medicinal chemistry, pharmaceutical research, and neurobiology, Trends in CNS Drug Discovery is also an ideal resource for graduate-level courses in neuroscience or pharmaceutical sciences.

Provides insights into the drug discovery innovations that are shaping future CNS therapies

In the vast field of neuroscience, drug discovery targeting the central nervous system (CNS) presents both extraordinary opportunities and complex challenges. Disorders such as Alzheimer’s disease, schizophrenia, and epilepsy affect millions worldwide, demanding innovative therapeutic strategies. Yet understanding brain processes and overcoming the blood-brain barrier continue to pose significant hurdles for researchers and developers alike.

Trends in CNS Drug Discovery offers a comprehensive overview of the methodologies, successes, and challenges shaping this critical area of pharmaceutical research. Covering a wide range of key areas, from current therapeutic paradigms to emerging technologies, this state-of-the-art volume brings together expertise from leading scientists and drug developers who address the role of cannabinoids and psychedelics in advancing CNS therapeutics, discuss emerging modalities such as protein degraders and allosteric modulators, examine funding strategies and academic-industrial collaborations, highlight advancements in brain-penetrating cancer treatments and other high-impact areas, and more.

Explores cutting-edge methodologies, including biomarkers, animal models, and brain imaging for CNS drug discovery Reviews innovative therapies such as combination drugs and prodrugs for improved treatment outcomes Analyzes challenges in targeting diseases including Alzheimer’s and schizophrenia with novel therapeutic strategies Includes real-world case studies demonstrating achievements and lessons in CNS drug development

A critical reference for academic researchers and industry professionals in medicinal chemistry, pharmaceutical research, and neurobiology, Trends in CNS Drug Discovery is also an ideal resource for graduate-level courses in neuroscience or pharmaceutical sciences.